Refine by
Patient Selection Articles & Analysis
102 news found
SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to identify patients with ecDNA amplified tumors using the SOPHiA DDM™ Platform. ...
FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. ...
ByBayer AG
In the New Drugs on the Horizon session at AACR, Bayer will present preclinical data on its novel selective diacylglycerol kinase (DGK) zeta inhibitor BAY 2965501, which is under Phase 1 clinical evaluation. ...
ByBayer AG
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
Treatment-emergent AEs led to dose reductions in 16 patients (31.4%) and to dose interruptions in 33 patients (64.7%). Seven patients (13.7%) discontinued treatment due to AEs. ...
“With darolutamide’s unprecedented survival data and minimal disruption to patients´ daily living across both mHSPC and high risk nmCRPC, following regulatory approval, we will be working to ensure that as many patients as possible benefit from darolutamide. ...
ByBayer AG
” Cellworks Precision Drug Development: Clinical Stage Clinical Trial Biosimulation: By biosimulating clinical trials, the Cellworks Platform may be able to predict human clinical response to pharmaceutical agents in just weeks, delivering critical insights years ahead of a traditional clinical trial. Patient cohorts are selected from the Cellworks ...
ABLE Care also allows the therapist to adjust the operating parameters of the exoskeleton, allowing rehabilitation therapy to be tailored to each patient’s needs. The application automatically saves the selected parameters in the patient’s profile, so the therapist does not have to adjust them again in the next rehabilitation session. ...
This award demonstrates the tremendous effort our team puts in everyday to develop technology that will benefit patients everywhere.” Iterative Health was selected from a pool of over 13,000 private companies and was chosen based on its R&D activity, market potential, business relationships, investor profile, competitive landscape, team strength, and ...
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...
MedAxiom, with the support of Daxor, recently completed a project to identify best practices to build a blueprint of how to operationalize BVA through a care pathway that focuses on everything from patient selection to monitoring, and operationally from strategy to billing. ...
” Significant mitral regurgitation prevalence rates are estimated to be up to 10% to 25% in patients in their seventies. During the procedure, operators implant one or more clips onto the valve leaflets with real-time echocardiographic imaging. Clinical data suggests MitraClip helps improve symptoms and survival in appropriately selected ...
“Glioblastoma remains one of the most aggressive and difficult to treat cancers globally and we believe that targeted radiotherapy and particularly ITM-31 can make a significant impact for patients by selectively eliminating tumor remnants post-surgery,” said Steffen Schuster, CEO of ITM. ...
We are fortunate to work together to advance this novel TCR product candidate through the first ever clinical development in the world.” Patients entering the trial are selected based on their expression of the KK-LC-1 antigen as determined by an immunohistochemistry assay. ...
25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of HTFC’s sponsors and the HTID health innovation ecosystem. The HealthTech Innovation Days (HTID®) event, organized by the HealthTech For Care ...
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its ...
ByBayer AG
Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study — a multi-center ...